Alluvi, known as BI 4744, presents a promising advance in weight management treatment. This dual activator targeting both GLP-1 and GIP sites demonstrates remarkable efficacy in patient assessments, potentially https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/